ZAMBIA CHOLERA VACCINES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Zambia cholera vaccines market was valued US$ 1.47 Mn in 2023 and is expected to reach US$ 4.25 Mn by 2031 exhibiting a compound annual growth rate (CAGR) of 14.2% from 2024 to 2031.

Cholera is a bacterial illness that typically spreads through tainted food and water. It causes severe diarrhea and dehydration. People can be protected against and immunized against cholera by receiving a vaccination. There are two varieties of these vaccines: oral O1 with whole-cell B subunit-killed and oral O1 & O139-killed. For all immunizations older than two years, this killed vaccine is well tolerated and offers high-level (85–90%) protection for six months following the second inoculation. Furthermore, vaccines that were five years old or older at the time of vaccination have a about 50% protection level after three years of immunization.

Figure 1. Zambia Cholera Vaccines Market Share (%), By Product, 2024

To learn more about this report, request a free sample copy

Analyst’s Views:

Zambia cholera vaccines market has strong growth potential over the next five years. The key driver for growth is the recurring cholera outbreaks witnessed across various regions of Zambia which have highlighted the need for a strategic vaccination program. Another major driver will be the various initiatives by government and non-governmental organization (NGOs) to promote vaccination as a low-cost preventive measure against the disease. However, factors such as low access in rural areas due to lack of proper cold chain infrastructure and cultural taboos surrounding vaccination may restrain market growth to some extent. The southern region of Zambia which includes towns like Livingstone is expected to be the fastest growing market for cholera vaccines. This is because the tourism dependent economy of this region is highly vulnerable to recurrent cholera outbreaks. Meanwhile, Lusaka is anticipated to maintain its dominance in the overall Zambia market with its position as the capital with maximum healthcare infrastructure and outreach programs. In the near future, vaccine uptake is likely to receive a boost through partnerships between global organizations like Global Alliance for Vaccines and Immunization (GAVI) and World Health Organization (WHO) with local health authorities. Increased advocacy and awareness campaigns especially during outbreaks will further drive responsible consumption of cholera vaccines across both public and private healthcare settings.

Zambia Cholera Vaccines Market- Drivers

• Increasing government initiatives: Increasing government initiatives is expected to drive the growth of the market over the forecast period. For instance, in June 2021, World Health Organization (WHO) supported the cholera vaccination campaign in Zambia’s hot spot districts as the country accelerates its efforts to eliminate the deadly disease. The World Health Organization has supported the country in conducting the situation analysis, mapping of the hotspots and has worked with the Global Alliance for Vaccines and Immunizations (GAVI) and the Global Task Force on Cholera Control (GTFCC) to ensure that the country receives the life-saving vaccines.
• Increasing adoption of inorganic growth strategies: Increasing adoption of inorganic growth strategies such as agreement by the key market players in the market is expected to drive the growth of the market over the forecast period. For instance, in November 2022, Biovac, a global pharmaceutical company, announced that it has entered into licensing and technology transfer agreement with the International Vaccine Institute (IVI), a non-profit international organization, for the manufacture of an oral cholera vaccine (OCV), for African and global market.

Zambia Cholera Vaccines Market- Opportunities

• Increasing launch of campaigns: Increasing launch of campaigns is expected to drive the growth of the market over the forecast period. For instance, in February 2022, the government of Zambia launched an oral cholera vaccination campaign in Lusaka, the country's capital, as part of efforts towards the elimination of the waterborne disease in the country. The campaign launched targets to vaccinate 1,038,000 eligible people from one year and above in the Zambian capital and follows vaccination campaigns conducted in seven of the 11 cholera-prone districts in the country.
• Expanding immunization programs: Expanding immunization programs could provide a great opportunity for growth in the Zambia cholera vaccines market. Cholera remains a major public health problem in Zambia, where outbreaks are still common especially during the rainy season. According to the World Health Organization (WHO), Zambia reported over 6,700 cholera cases and 118 deaths from January to October 2020 alone. With such a high disease burden, scaling up vaccination programs could help contain the spread of the disease. Vaccination programs in Zambia are limited in scale and coverage. They primarily focus on reactive vaccination during outbreaks rather than establishing sustained immunization infrastructure. This temporary, outbreak-based approach is unable to achieve long-term protection or herd immunity in communities at risk. A few oral cholera vaccination campaigns have been conducted with support from international organizations like the WHO, but vaccination levels remain low across the country. Expanding these preliminary immunization efforts into a standardized, multi-year routine cholera vaccination strategy could drive significant and sustained demand for cholera vaccines.

Zambia Cholera Vaccines Market – Trends

• Increasing initiatives by the government organizations: Increasing initiatives by the government organization is expected to drive the growth of the market over the forecast period. For instance, on February 9, 2024, by Star Media Group Berhad, the World Health Organization (WHO) has agreed to give Zambia more oral cholera vaccines to help the country tackle the waterborne disease outbreak. The WHO has approved Zambia's request for an additional 1.9 million doses of oral cholera vaccine.

Zambia Cholera Vaccines Market - Restraints

• High cost for drug development: High cost of drug development is one of the major restraints impacting the growth of Zambia cholera vaccines market. Developing an effective vaccine involves extensive research and clinical trials which requires huge investments. Antibiotics are the only available treatment options for cholera vaccines, and many pharmaceutical companies are working on developing non-antibiotic alternatives. For important market players, creating a new class of medications will present numerous growth prospects, and will also necessitate significant financial outlays for the research and development (R&D) of innovative treatments. The comparatively large investment needs could impede market expansion.
• Longer time required for production of vaccine: The length of time needed to produce a batch of vaccines can serve as a market restriction. The duration varies significantly depending on the manufacturing size, ranging from 41.2 hours for a 1 L process to 48.2 hours for a 30 L process. As a result, it limits the market
• Counterbalance: The key market players should focus on developing technologies which will reduce time and cost for production of vaccines.

Figure 2. Zambia Cholera Vaccines Market Share (%), By End User, 2024

To learn more about this report, request a free sample copy

Zambia Cholera Vaccines Market- Recent Developments

• On January 20, 2024, Africa Centres for Disease Control and Prevention (CDC), is a public health agency of the African Union to support the public health initiatives of member states and strengthen the capacity of their health institutions to deal with disease threats, sensitised Heads of State and Government from the Southern Africa Development Community (SADC) regarding the increase of cholera-related cases and deaths in the region. Heads of State and Government then decided to organize an extraordinary summit hosted by the SADC Secretariat and led by President Lourenco from Angola as the Chair of SADC. This meeting was held virtually on February02, 2024 to receive and consider a report on the status of the cholera outbreak in the SADC region. They expressed concern on the progress made in curbing the situation and the challenges that continue to hamper the effective fight against the recurrent outbreaks.
• In August 2023, GC Biopharma, a global pharmaceutical company, signed a memorandum of understanding (MOU) with Eubiologics, a global biotechnology company to jointly manufacture oral cholera vaccine, Euvichol. The parties will jointly manufacture Euvichol from the first half of 2024 for supply to the United Nations International Children’s Emergency Fund (UNICEF). UNICEF had sought further supply of vaccines apart from those of a plastic-tubed Euvichol-Plus to address the recent spread of cholera infection in various areas such as Africa.

Top Companies in the Zambia Cholera Vaccines Market

• Biovac Inc.
• Valneva SE.
• EMERGENT
• Astellas Pharma Inc.
• Sanofi
• EUBIOLOGICS CO., LTD
• Johnson & Johnson Services Inc.
• Celldex Therapeutics.

Definition: Cholera Vaccine is an inactivated vaccine and contains vibrios of the serotypes Inaba and Ogawa. Cholera is an acute diarrhoeal disease that can kill a person within hours if left untreated. Cholera is a disease of poverty affecting people with inadequate access to safe water and basic sanitation.